ZA200601526B - [1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia - Google Patents
[1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia Download PDFInfo
- Publication number
- ZA200601526B ZA200601526B ZA200601526A ZA200601526A ZA200601526B ZA 200601526 B ZA200601526 B ZA 200601526B ZA 200601526 A ZA200601526 A ZA 200601526A ZA 200601526 A ZA200601526 A ZA 200601526A ZA 200601526 B ZA200601526 B ZA 200601526B
- Authority
- ZA
- South Africa
- Prior art keywords
- disorder
- piperazin
- disorders
- butoxy
- naphthyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 69
- 201000000980 schizophrenia Diseases 0.000 title claims description 11
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical class C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 title claims description 6
- 150000003839 salts Chemical class 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 208000028017 Psychotic disease Diseases 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 208000019901 Anxiety disease Diseases 0.000 claims description 16
- 206010012335 Dependence Diseases 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- -1 cyano, hydroxy Chemical group 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 208000020401 Depressive disease Diseases 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 208000020925 Bipolar disease Diseases 0.000 claims description 12
- 206010012289 Dementia Diseases 0.000 claims description 12
- 208000023105 Huntington disease Diseases 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 230000036506 anxiety Effects 0.000 claims description 12
- 208000024732 dysthymic disease Diseases 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 208000015238 neurotic disease Diseases 0.000 claims description 11
- 208000016285 Movement disease Diseases 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 208000024714 major depressive disease Diseases 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 208000008811 Agoraphobia Diseases 0.000 claims description 8
- 208000027691 Conduct disease Diseases 0.000 claims description 8
- 208000019022 Mood disease Diseases 0.000 claims description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 8
- 239000003176 neuroleptic agent Substances 0.000 claims description 8
- 230000000701 neuroleptic effect Effects 0.000 claims description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 230000003542 behavioural effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000019906 panic disease Diseases 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 208000021465 Brief psychotic disease Diseases 0.000 claims description 5
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 5
- 208000019568 Shared Paranoid disease Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
- 206010001541 Akinesia Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 4
- 206010008748 Chorea Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 206010012218 Delirium Diseases 0.000 claims description 4
- 206010012239 Delusion Diseases 0.000 claims description 4
- 208000024254 Delusional disease Diseases 0.000 claims description 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 208000004547 Hallucinations Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 4
- 206010026749 Mania Diseases 0.000 claims description 4
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 4
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 206010034912 Phobia Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 4
- 206010037213 Psychomotor retardation Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 201000000552 Scott syndrome Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 208000013200 Stress disease Diseases 0.000 claims description 4
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 208000016620 Tourette disease Diseases 0.000 claims description 4
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000012826 adjustment disease Diseases 0.000 claims description 4
- 201000002426 animal phobia Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 208000025748 atypical depressive disease Diseases 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 208000028683 bipolar I disease Diseases 0.000 claims description 4
- 208000030963 borderline personality disease Diseases 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 229960003920 cocaine Drugs 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 231100000868 delusion Toxicity 0.000 claims description 4
- 229960002069 diamorphine Drugs 0.000 claims description 4
- 208000035548 disruptive behavior disease Diseases 0.000 claims description 4
- 208000010118 dystonia Diseases 0.000 claims description 4
- 230000001667 episodic effect Effects 0.000 claims description 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 4
- 206010020765 hypersomnia Diseases 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 201000003995 melancholia Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 229960002715 nicotine Drugs 0.000 claims description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 230000001144 postural effect Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 208000018198 spasticity Diseases 0.000 claims description 4
- 201000001716 specific phobia Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000002618 waking effect Effects 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 208000001613 Gambling Diseases 0.000 claims description 3
- 206010022998 Irritability Diseases 0.000 claims description 3
- 208000036626 Mental retardation Diseases 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 229940049706 benzodiazepine Drugs 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 208000026725 cyclothymic disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 208000025319 neurotic depression Diseases 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 2
- 229910020008 S(O) Inorganic materials 0.000 claims description 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000003444 phase transfer catalyst Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 13
- 239000013543 active substance Substances 0.000 claims 5
- 239000002249 anxiolytic agent Substances 0.000 claims 5
- 208000026139 Memory disease Diseases 0.000 claims 3
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 206010021654 increased appetite Diseases 0.000 claims 3
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 claims 3
- 208000012672 seasonal affective disease Diseases 0.000 claims 3
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 150000001557 benzodiazepines Chemical class 0.000 claims 2
- JGXADKQUHQKYGM-UHFFFAOYSA-N 4,4-dimethyl-7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-1,3-dihydro-1,8-naphthyridin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCOC=3N=C4NC(=O)CC(C4=CC=3)(C)C)=CC=CC2=C1 JGXADKQUHQKYGM-UHFFFAOYSA-N 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000020186 Schizophreniform disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- XEKAWZARUWARND-UHFFFAOYSA-N 6h-oxazin-3-one Chemical compound O=C1NOCC=C1 XEKAWZARUWARND-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- PBKIRZJZSDIVTH-UHFFFAOYSA-N 1-methyl-7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-1,8-naphthyridin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCOC=3N=C4N(C(C=CC4=CC=3)=O)C)=CC=CC2=C1 PBKIRZJZSDIVTH-UHFFFAOYSA-N 0.000 description 1
- RCAKDAJNTQWAHM-UHFFFAOYSA-N 2-[4-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]butoxy]-4-methyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(=O)NC2=NC(OCCCCN3CCN(CC3)C3=CC=CC4=CC=C(C=C43)OC)=NC(C)=C21 RCAKDAJNTQWAHM-UHFFFAOYSA-N 0.000 description 1
- XISPDDYROWQPHI-UHFFFAOYSA-N 3,4-dihydro-1h-pyrido[2,3-d]pyrimidin-2-one Chemical compound C1=CN=C2NC(=O)NCC2=C1 XISPDDYROWQPHI-UHFFFAOYSA-N 0.000 description 1
- FRRCBCQAPVGEOO-UHFFFAOYSA-N 7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-3-(2,2,2-trifluoroethyl)-1h-1,8-naphthyridin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCOC3=CC=C4C=C(C(NC4=N3)=O)CC(F)(F)F)=CC=CC2=C1 FRRCBCQAPVGEOO-UHFFFAOYSA-N 0.000 description 1
- VUBUZHIIKCQCJT-UHFFFAOYSA-N 7-[4-[4-(2,3-dihydro-1h-inden-4-yl)piperazin-1-yl]butoxy]-5-(trifluoromethyl)-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=C1N=C(OCCCCN1CCN(CC1)C=1C=3CCCC=3C=CC=1)C=C2C(F)(F)F VUBUZHIIKCQCJT-UHFFFAOYSA-N 0.000 description 1
- NTSIPJBZBHNELB-UHFFFAOYSA-N 7-[4-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound CC(C)OC1=CC=CC=C1N1CCN(CCCCOC=2N=C3NC(=O)CCC3=CC=2)CC1 NTSIPJBZBHNELB-UHFFFAOYSA-N 0.000 description 1
- NUMFTMZHUMXZAA-UHFFFAOYSA-N 7-[4-[4-(6-acetylnaphthalen-1-yl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1CC(=O)NC2=NC(OCCCCN3CCN(CC3)C=3C4=CC=C(C=C4C=CC=3)C(=O)C)=CC=C21 NUMFTMZHUMXZAA-UHFFFAOYSA-N 0.000 description 1
- VKMHCMKLABZWBE-UHFFFAOYSA-N 7-[4-[4-(6-ethylpyridin-2-yl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound CCC1=CC=CC(N2CCN(CCCCOC=3N=C4NC(=O)CCC4=CC=3)CC2)=N1 VKMHCMKLABZWBE-UHFFFAOYSA-N 0.000 description 1
- ZSQZRCKMKVDNTH-UHFFFAOYSA-N 7-[4-[4-(7,8-difluoronaphthalen-1-yl)piperazin-1-yl]butoxy]-1h-1,8-naphthyridin-2-one Chemical compound C1=CC(=O)NC2=NC(OCCCCN3CCN(CC3)C3=CC=CC4=CC=C(C(=C43)F)F)=CC=C21 ZSQZRCKMKVDNTH-UHFFFAOYSA-N 0.000 description 1
- OGRSKOZAEWWGJV-UHFFFAOYSA-N 7-[4-[4-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]butoxy]-1h-1,8-naphthyridin-2-one Chemical compound C1=CC(=O)NC2=NC(OCCCCN3CCN(CC3)C=3C=CC=C4CCC(CC4=3)O)=CC=C21 OGRSKOZAEWWGJV-UHFFFAOYSA-N 0.000 description 1
- CWTJQUTVIHEYAZ-UHFFFAOYSA-N 7-[5-[4-(2,3-dichlorophenyl)piperazin-1-yl]pentan-2-yloxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1C=C2CCC(=O)NC2=NC=1OC(C)CCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl CWTJQUTVIHEYAZ-UHFFFAOYSA-N 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49737003P | 2003-08-22 | 2003-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601526B true ZA200601526B (en) | 2007-04-25 |
Family
ID=34216117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601526A ZA200601526B (en) | 2003-08-22 | 2006-02-21 | [1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US7160888B2 (sr) |
| EP (1) | EP1660497A1 (sr) |
| JP (1) | JP4034811B2 (sr) |
| KR (2) | KR100801794B1 (sr) |
| CN (1) | CN100422181C (sr) |
| AP (1) | AP2006003525A0 (sr) |
| AR (1) | AR045386A1 (sr) |
| AU (1) | AU2004266191B2 (sr) |
| BR (1) | BRPI0413860A (sr) |
| CA (1) | CA2538915C (sr) |
| CR (2) | CR8254A (sr) |
| CU (1) | CU23464B7 (sr) |
| EA (1) | EA009645B1 (sr) |
| EC (1) | ECSP066391A (sr) |
| GE (1) | GEP20084447B (sr) |
| GT (1) | GT200500007A (sr) |
| HN (1) | HN2004000319A (sr) |
| IL (1) | IL173439A0 (sr) |
| IS (1) | IS8267A (sr) |
| MA (1) | MA28003A1 (sr) |
| ME (1) | MEP45308A (sr) |
| MX (1) | MXPA06002070A (sr) |
| MY (1) | MY140693A (sr) |
| NL (1) | NL1026892C2 (sr) |
| NO (1) | NO20060324L (sr) |
| NZ (1) | NZ545078A (sr) |
| OA (1) | OA13238A (sr) |
| PA (1) | PA8609701A1 (sr) |
| PE (1) | PE20051039A1 (sr) |
| RS (1) | RS20060129A (sr) |
| TN (1) | TNSN06063A1 (sr) |
| TW (1) | TWI298327B (sr) |
| UA (1) | UA82541C2 (sr) |
| WO (1) | WO2005019215A1 (sr) |
| ZA (1) | ZA200601526B (sr) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| US7504395B2 (en) * | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| MXPA06013941A (es) | 2004-06-08 | 2007-12-10 | Neurosearch Sweden Ab | Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina. |
| CA2569843A1 (en) * | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| FR2877005A1 (fr) * | 2004-10-22 | 2006-04-28 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
| JP2008528604A (ja) | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
| WO2006090272A1 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia |
| WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| EA200701856A1 (ru) * | 2005-04-01 | 2008-02-28 | Уорнер-Ламберт Компани Ллс | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении |
| MX2007012463A (es) * | 2005-04-08 | 2007-11-07 | Pfizer Prod Inc | Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i. |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| RU2402549C3 (ru) * | 2005-04-14 | 2022-03-10 | Оцука Фармасьютикал Ко., Лтд. | Пиперазин-замещенные бензотиофены для лечения психических расстройств |
| TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
| PT1940839E (pt) | 2005-10-07 | 2013-10-10 | Exelixis Inc | Inibidores de piridopirimidinona pi3k alfa |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| WO2007052104A2 (en) * | 2005-10-31 | 2007-05-10 | Pfizer Products Inc. | Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one |
| EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| WO2007116265A1 (en) * | 2006-03-31 | 2007-10-18 | Pfizer Products Inc. | Process for making a tetrahydro-pyridoazepin-8-one compound |
| US8604031B2 (en) | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| CA2663401C (en) * | 2006-09-15 | 2011-07-12 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| US20100093738A1 (en) * | 2006-10-06 | 2010-04-15 | Basf Se | Fungicidal Compounds and Fungicidal Compositions |
| AR063302A1 (es) * | 2006-10-13 | 2009-01-21 | Otsuka Pharma Co Ltd | Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla. |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| WO2008084324A1 (en) * | 2007-01-04 | 2008-07-17 | Pfizer Products Inc. | Naphthyridinone compound |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| RU2497819C2 (ru) * | 2007-05-21 | 2013-11-10 | Ривайва Фармасьютикалс, Инк. | Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина |
| US20090042874A1 (en) * | 2007-05-30 | 2009-02-12 | Wyeth | Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans |
| US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| JP5323088B2 (ja) | 2007-12-18 | 2013-10-23 | アクテリオン ファーマシューティカルズ リミテッド | ５−アミノシクリルメチル−オキサゾリジン−２−オン誘導体 |
| JP2011529090A (ja) | 2008-07-28 | 2011-12-01 | 江蘇国華投資有限公司 | アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用 |
| EP3085699B1 (en) | 2008-07-31 | 2022-03-02 | Firmenich Incorporated | Processes for making sweet taste enhancers |
| CN102232078B (zh) | 2008-12-12 | 2014-07-16 | 埃科特莱茵药品有限公司 | 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物 |
| EP2389379A1 (en) * | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| CN102413830A (zh) * | 2009-02-26 | 2012-04-11 | 雷维瓦药品公司 | 利用芳基哌嗪衍生物的组合物、合成及方法 |
| PT2445502T (pt) | 2009-06-25 | 2017-09-22 | Alkermes Pharma Ireland Ltd | Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos |
| JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ |
| JP5857040B2 (ja) | 2010-05-04 | 2016-02-10 | アルカーメス ファーマ アイルランド リミテッド | 酸化ラクタム化合物の合成方法 |
| NZ604423A (en) | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US9156822B2 (en) | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
| CA2817460A1 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| WO2013088255A1 (en) | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| WO2013142202A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| CN104785295B (zh) * | 2015-03-18 | 2018-03-06 | 杭州创培信息科技有限公司 | 一种高选择性多巴胺铂炭催化剂的制备方法 |
| HK1255074A1 (zh) | 2015-07-01 | 2019-08-02 | Crinetics Pharmaceuticals, Inc. | 生长抑素调节剂及其用途 |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| CN106242934A (zh) * | 2016-07-26 | 2016-12-21 | 云南民族大学 | 一种酮的β‑位C‑H键乙酰氧化合成方法 |
| EP4151627A1 (en) * | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| WO2020033420A1 (en) | 2018-08-07 | 2020-02-13 | Firmenich Incorporated | 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof |
| MY210507A (en) | 2018-08-13 | 2025-09-28 | Hoffmann La Roche | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| PH12022550339A1 (en) | 2019-09-12 | 2023-03-13 | Hoffmann La Roche | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| CN114634479B (zh) * | 2020-12-16 | 2025-02-07 | 北京盈科瑞创新药物研究有限公司 | 一种派嗪衍生物、其制备方法及应用 |
| US20240217977A1 (en) * | 2021-03-31 | 2024-07-04 | Blueprint Medicines Corporation | Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023186023A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州旺山旺水生物医药股份有限公司 | 一类n-取代的喹啉酮化合物、其制备方法和用途 |
| CN114805081B (zh) * | 2022-05-20 | 2024-09-24 | 都创(上海)医药开发有限公司 | 一种基于微通道连续流技术快速制备1-萘胺的方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5649361A (en) | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| JPH07165720A (ja) * | 1988-10-31 | 1995-06-27 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤 |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| HU207310B (en) | 1988-12-02 | 1993-03-29 | Pfizer | Process for producing aryl-piperidine derivatives |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5350747A (en) | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| WO1991000863A1 (en) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
| US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
| MX9201991A (es) | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
| NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| US5206366A (en) | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| KR100190730B1 (ko) | 1992-12-17 | 1999-06-01 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸 |
| TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
| TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| DK0674624T3 (da) | 1992-12-17 | 1999-09-13 | Pfizer | Pyrazoler med CRF-antagonistisk aktivitet |
| BR9307646A (pt) | 1992-12-17 | 1999-05-25 | Pfizer | Pirrolopirimidinas como antagonistas de crf |
| FR2699918B1 (fr) | 1992-12-30 | 1995-03-17 | Pf Medicament | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. |
| JPH07247271A (ja) * | 1994-01-21 | 1995-09-26 | Otsuka Pharmaceut Co Ltd | ３，４−ジヒドロカルボスチリル誘導体 |
| FR2731222A1 (fr) | 1995-03-02 | 1996-09-06 | Pf Medicament | Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments |
| JP2900130B2 (ja) * | 1995-03-16 | 1999-06-02 | 大塚製薬株式会社 | カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤 |
| JP2987484B2 (ja) * | 1995-03-16 | 1999-12-06 | 大塚製薬 株式会社 | カルボスチリル誘導体の製造方法 |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| WO1997003067A1 (en) | 1995-07-13 | 1997-01-30 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
| WO1997014419A1 (en) | 1995-10-20 | 1997-04-24 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| JPH09241161A (ja) | 1996-03-08 | 1997-09-16 | Nippon Shinyaku Co Ltd | 医 薬 |
| US5912256A (en) | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| FR2761071B1 (fr) | 1997-03-20 | 1999-12-03 | Synthelabo | Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique |
| FR2769912B1 (fr) | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine |
| DE19747063A1 (de) | 1997-10-24 | 1999-04-29 | Basf Ag | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
| US6267784B1 (en) | 1998-05-01 | 2001-07-31 | Benz Research And Development Corporation | Intraocular lens and haptics made of a copolymer |
| EP1246822A1 (en) | 1999-12-20 | 2002-10-09 | Eli Lilly And Company | Benzofuran derivatives |
| DE10041574A1 (de) | 2000-08-24 | 2002-03-07 | Merck Patent Gmbh | Chromenonderivate |
| WO2002048105A2 (en) | 2000-11-16 | 2002-06-20 | Wyeth | Aryloxy piperidinyl derivatives for the treatment of depression |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| UA75407C2 (en) | 2001-06-29 | 2006-04-17 | Lundbeck & Co As H | Heteroaryl derivatives of pyridine and pyrimidine, pharmaceutical composition and use thereof |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| TW200507841A (en) | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
-
2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active Expired - Fee Related
- 2004-08-13 CA CA2538915A patent/CA2538915C/en not_active Expired - Fee Related
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 EP EP04744287A patent/EP1660497A1/en not_active Withdrawn
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active Expired - Fee Related
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/en not_active Ceased
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
-
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
-
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
-
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI754438B (zh) | 取代的雜環并環類化合物，其製法與醫藥上的用途 | |
| JP4034811B2 (ja) | 統合失調症の治療のための［１，８］ナフチリジン−２−オンおよび関連化合物 | |
| CN101671336B (zh) | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 | |
| AU2005217199B2 (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | |
| EP1549651B1 (en) | Pyrimidopyrimidones as kinase inhibitors | |
| US9216978B2 (en) | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases | |
| CN103946222B (zh) | 作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物 | |
| AU2009211338A1 (en) | Pyrrolo[2, 3-D] pyrimidines and use thereof as tyrosine kinase inhibitors | |
| WO2024026076A2 (en) | Substituted 3,4-dihydroquinolinone inhibitors of tshr | |
| KR950703567A (ko) | O-알킬화된 라파미신 유도체 및 면역 억제제로서의 용도 (o-alkylated rapamycin derivatives and their use, particularly as immuno-suppressants) | |
| AU2012222869B2 (en) | Methods of treating a disease or condition of the central nervous system | |
| MX2007000457A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| AU2002247059B2 (en) | Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | |
| CN103917530A (zh) | 作为mtor抑制剂的吗啉代取代的脲或氨基甲酸衍生物 | |
| JPH07502278A (ja) | イミダゾキナゾリン化合物並びにそれらの製剤および使用 | |
| MXPA04006030A (es) | Antiviricos de piridoquinoxalina. | |
| CA3120614A1 (en) | Inhibitors of gli1 as therapeutic agents | |
| EP3750885A1 (en) | Compound having bet inhibitory activity and preparation method and use therefor | |
| ZA200502216B (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia. | |
| KR0145181B1 (ko) | 신규 벤조 [1,8] 나프티리딘 유도체 및 그의 제법 | |
| CN103554111A (zh) | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 | |
| CN102372712B (zh) | 咪唑并二氮杂萘类PI3K和mTOR双重抑制剂 | |
| Krishnamurthy et al. | Synthesis of 3-(2-chloroethyl)-2-methyl-6, 7, 8, 9-tetrahydro-4H-pyrido [1, 2-a] pyrimidin-4-one Derivatives as Antibacterial Agents | |
| CA3293795A1 (en) | 3-phenylpropylamine derivative | |
| Harper | Patent News: Renin Angiotensin System Agents and Anti-atherosclerotic Agents |